Authors

Latest:

Rehabilitation Should Be Part of Cancer Treatment

Rehabilitation is medical care that cancer patients should expect and that it should be delivered by trained rehabilitation professionals: physiatrists, physical therapists, occupational therapists, or speech language pathologists.

Erica Bell, PhD

Latest:

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Erica DiNapoli

Erica DiNapoli is an Assistant Editor for

Latest:

Chasing Survival Benefit With Novel Systemic Strategies in Early-Stage NSCLC

Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.

Erica L. Mayer, MD, MPH

Latest:

Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Erik J. Blok, MD

Latest:

Dr. Blok on Results of Adjuvant Letrozole Study in Breast Cancer

Erik J. Blok, MD, Department of Medical Oncology at Leiden University Medical Center, discusses the duration of adjuvant endocrine therapy. Blok claims that there is no breast cancer survival benefit in extending adjuvant letrozole treatment from 2.5 to 5 years.

Erik P. Castle, MD

Latest:

Dr. Castle on Minimally Invasive Surgical Approaches in RCC

Erik P. Castle, MD, discusses minimally invasive surgical approaches in renal cell carcinoma.

Erika N. Brown, BS, MS, PharmD

Latest:

Triple Receptor-Negative Breast Cancer: Current and Future Treatments

Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.

Erika P. Hamilton, MD

Latest:

Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast Cancer

Erika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.

Erika P. Hamilton, MD, Sarah Cannon Research Institute

Latest:

Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika Hamilton

OncLive sits down with Erika P. Hamilton, MD, and Milind Javle, MD, on the pivotal studies in breast cancer and gastrointestinal cancers, respectively, at the 2021 ASCO Annual Meeting.

Erin A. Gillaspie, MD, MPH

Latest:

Neoadjuvant Immunotherapy May Change Standard of Care in Early-Stage NSCLC

Wade T. Iams, MD, and Erin A. Gillaspie, MD, MPH, discuss the impact that immunotherapy has had on the treatment of patients with early-stage non–small cell lung cancer.

Erin Burns, PhD

Latest:

Pandemic Intensifies the Struggle With Burnout in Cancer Field

The COVID-19 pandemic has added another burden, with growing evidence of its negative effects on the well-being of many cancer care providers.

Erin Crum, MPH

Latest:

McKesson's Patient-Reported Outcomes Measure Will Track Improvements in Health-Related Social Needs

The use of patient-reported outcome measures—the gold standard in quality measurement—is crucial to building a patient-centered, value-based care system.

Erin F. Gillespie, MD, Neil Panjwani, BS, Arno J. Mundt, MD

Latest:

eContour: Evidence-Based Interactive Contouring Resources at the Point of Care

eContour is a novel, web-based, interactive contouring resource that aims to facilitate access to decision support through high-yield radiation treatment recommendations that are free and available at the point of care.

Erin Hofstatter, MD

Latest:

Clinical Utility of Emerging Molecular Diagnostics in Breast Cancer

The past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.

Erin K. Crane, MD, MPH

Latest:

Dr Crane on the Ongoing Investigation of PARP Inhibitor Combinations in Ovarian Cancer

Erin Kopp

Latest:

Erin Kopp on the Toxicities of Cutaneous T-cell Lymphoma Treatment

Erin Kopp, ACNP-BC, City of Hope Comprehensive Cancer Center, on managing the side effects of cutaneous T-cell lymphoma treatment.

Erin M. Bertino, MD

Latest:

Dr. Bertino on the Impact of the EGFR-Mutated Subset Analysis of IMpower150 in NSCLC

Erin M. Bertino, MD, discusses the impact of the EGFR-mutated subset analysis of the phase 3 IMpower150 trial on the use of immunotherapy in patients with non–small cell lung cancer.

Erin M. Burns, PhD, MSPH

Latest:

Advanced Practice Providers Are Poised to Boost Community Involvement in Clinical Trials

For those in the community setting, several barriers to clinical research prevent advanced care providers and their patients from taking part in experimental therapies.

Erin McMenamin, MSN

Latest:

Erin McMenamin on Head and Neck Cancer Treatments

Erin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses treatments for HPV-positive head and neck cancer, which tends to have a better prognosis than HPV-negative head and neck cancers.

Erin Murphy, MD

Latest:

Dr. Murphy on Remaining Questions With SBRT in Pediatric Sarcoma

Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.